Logo image of CLVR

CLEVER LEAVES HOLDINGS INC (CLVR) Stock Fundamental Analysis

NASDAQ:CLVR - Nasdaq - CA1867602031 - Common Stock - Currency: USD

3  +0.89 (+42.18%)

After market: 3.05 +0.05 (+1.67%)

Fundamental Rating

2

Overall CLVR gets a fundamental rating of 2 out of 10. We evaluated CLVR against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CLVR have multiple concerns. CLVR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLVR has reported negative net income.
In the past year CLVR has reported a negative cash flow from operations.
CLVR had negative earnings in each of the past 5 years.
In the past 5 years CLVR always reported negative operating cash flow.
CLVR Yearly Net Income VS EBIT VS OCF VS FCFCLVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -57.31%, CLVR is doing worse than 62.56% of the companies in the same industry.
The Return On Equity of CLVR (-73.94%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.31%
ROE -73.94%
ROIC N/A
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
CLVR Yearly ROA, ROE, ROICCLVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Gross Margin of CLVR (37.63%) is comparable to the rest of the industry.
CLVR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CLVR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
CLVR Yearly Profit, Operating, Gross MarginsCLVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

CLVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLVR has more shares outstanding
The number of shares outstanding for CLVR has been increased compared to 5 years ago.
The debt/assets ratio for CLVR is higher compared to a year ago.
CLVR Yearly Shares OutstandingCLVR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
CLVR Yearly Total Debt VS Total AssetsCLVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.24, we must say that CLVR is in the distress zone and has some risk of bankruptcy.
CLVR has a Altman-Z score of -9.24. This is in the lower half of the industry: CLVR underperforms 76.41% of its industry peers.
CLVR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
CLVR's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. CLVR outperforms 51.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -9.24
ROIC/WACCN/A
WACC10.07%
CLVR Yearly LT Debt VS Equity VS FCFCLVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.40 indicates that CLVR has no problem at all paying its short term obligations.
CLVR has a Current ratio of 2.40. This is in the lower half of the industry: CLVR underperforms 60.00% of its industry peers.
CLVR has a Quick Ratio of 1.63. This is a normal value and indicates that CLVR is financially healthy and should not expect problems in meeting its short term obligations.
CLVR has a worse Quick ratio (1.63) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.63
CLVR Yearly Current Assets VS Current LiabilitesCLVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

CLVR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.15%, which is quite impressive.
The Revenue has been growing slightly by 4.80% in the past year.
The Revenue has been growing by 12.85% on average over the past years. This is quite good.
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 128.91% on average over the next years. This is a very strong growth
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLVR Yearly Revenue VS EstimatesCLVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CLVR Yearly EPS VS EstimatesCLVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLVR Price Earnings VS Forward Price EarningsCLVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLVR Per share dataCLVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CLVR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEVER LEAVES HOLDINGS INC

NASDAQ:CLVR (5/16/2024, 8:00:00 PM)

After market: 3.05 +0.05 (+1.67%)

3

+0.89 (+42.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-23 2024-05-23/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners2.55%
Inst Owner Change-22.23%
Ins Owners342.65%
Ins Owner Change0%
Market Cap5.25M
Analysts43.33
Price Target24.48 (716%)
Short Float %0.54%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.79%
Min Revenue beat(2)-27.98%
Max Revenue beat(2)-21.6%
Revenue beat(4)1
Avg Revenue beat(4)-10.9%
Min Revenue beat(4)-27.98%
Max Revenue beat(4)8.33%
Revenue beat(8)3
Avg Revenue beat(8)-12.3%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-11.4
EYN/A
EPS(NY)-6.73
Fwd EYN/A
FCF(TTM)-6.59
FCFYN/A
OCF(TTM)-6.58
OCFYN/A
SpS9.95
BVpS13.84
TBVpS12.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.31%
ROE -73.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.63%
FCFM N/A
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
F-Score3
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.31%
Cap/Sales 0.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 1.63
Altman-Z -9.24
F-Score3
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)81.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)18.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.41%
OCF growth 3YN/A
OCF growth 5YN/A